Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
BPH Impact IndexBosniak ClassificationCAPRA ScoreD'Amico Risk ClassificationEAU NMIBC Risk Groups (2021)EORTC Risk Tables for NMIBCFournier's Gangrene Severity IndexGUPI (Genitourinary Pain Index)Guy's Stone ScoreICIQ-UI SFIGCCCG ClassificationIIEF-5 / SHIMIIQ-7IMDC (Heng) Risk CriteriaIPSS ScoreNIH-CPSIOAB-V8PADUA Prediction ScorePI-RADS v2.1PSA DensityR.E.N.A.L. Nephrometry ScoreResidual Volume (PVR)S.T.O.N.E. NephrolithometrySFU Hydronephrosis GradingUDI-6VUR Grading
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Recent Journal Updates

Cancer MedicineJun 13, 2026
Worse Function and Symptoms Among the Most Rural Patients With Advanced Cancer: A Cross‐Sectional Analysis

Clinical Context

We think this might be relevant to the clinical guidance for International Prostate Symptom Score (IPSS).

British J Clinical PharmacologyJun 11, 2026
S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis

Clinical Context

We think this might be relevant to the clinical guidance for International Prostate Symptom Score (IPSS).

Intensive Care MedicineJun 10, 2026
“It was torture for him, and it was torture for us to see him like that”: understanding multiple ICU-related triggers of family PTSD symptoms—a qualitative thematic study

Clinical Context

We think this might be relevant to the clinical guidance for International Prostate Symptom Score (IPSS).

IPSS Score

Benign Prostatic Hyperplasia Screening

IPSS Questionnaire

Over the past month, how often have you had a sensation of not emptying your bladder completely after you finish urinating?

Over the past month, how often have you had to urinate again less than two hours after you finished urinating?

Over the past month, how often have you found you stopped and started again several times when you urinated?

Over the past month, how often have you found it difficult to postpone urination?

Over the past month, how often have you had a weak urinary stream?

Over the past month, how often have you had to push or strain to begin urination?

Over the past month, how many times did you most typically get up to urinate from the time you went to bed until the time you got up in the morning?

If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?

Awaiting Responses

Answer all 7 symptom questions and the 1 quality of life question to calculate the IPSS.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

When to Use the IPSS

Screening for lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)
Initial assessment and quantification of symptom severity in men with voiding or storage complaints
Monitoring disease progression or response to medical therapy (alpha-blockers, 5-alpha reductase inhibitors, PDE5 inhibitors, combination therapy)
Pre- and post-operative evaluation after surgical interventions for BPH (TURP, laser enucleation, Urolift, Rezum, etc.)
Shared decision-making regarding treatment escalation or de-escalation
Research studies and clinical registries for BPH outcomes
Longitudinal follow-up in primary care or urology clinics

Clinical Context

Lower urinary tract symptoms (LUTS) due to BPH affect over 50% of men above age 60 and significantly impact quality of life. The IPSS, originally developed as the American Urological Association (AUA) Symptom Index, is the most widely used, validated, and internationally accepted tool for quantifying LUTS severity. It is quick to complete (usually < 5 minutes) and provides an objective measure that complements history, physical examination (including digital rectal exam), and uroflowmetry.

Key Domains Assessed

Voiding symptoms (weak stream, intermittency, straining, incomplete emptying)
Storage symptoms (frequency, urgency, nocturia)
Overall bother and quality of life due to urinary symptoms

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the BPH Impact Index, PSA Density, UDI-6, ICIQ-UI SF or the ABSI (Burn Severity) to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Related Urology Tools

BPH Impact Index
PSA Density
UDI-6
ICIQ-UI SF
NIH-CPSI
VUR Grading
EORTC Risk Tables for NMIBC
R.E.N.A.L. Nephrometry Score
CAPRA Score
IMDC
Urology CalculatorsInternal Medicine CalculatorsEmergency Medicine Calculators
Have feedback about this calculator?Let us know.